• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why MannKind (MNKD) Is Down 5.3% After Dual Lung And Heart Failure Milestones And What's Next

    Simply Wall St·08/01/2026 16:24:50
    Listen to the news
    • In late July 2026, MannKind reported positive topline Phase 1b results for its inhaled nintedanib in idiopathic pulmonary fibrosis and secured FDA approval for Furoscix ReadyFlow, an at-home furosemide autoinjector for adults with heart failure or chronic kidney disease.
    • Together, these milestones highlight MannKind’s push to extend its Technosphere and drug-delivery expertise into chronic lung disease and out-of-hospital heart failure care, broadening its potential revenue sources beyond diabetes.
    • Next, we’ll examine how the Furoscix ReadyFlow approval shapes MannKind’s investment narrative and its efforts to diversify beyond Afrezza.

    The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

    MannKind Investment Narrative Recap

    To own MannKind today, you need to believe its Technosphere platform can support a broader, commercially meaningful portfolio beyond Afrezza and Tyvaso DPI royalties, while the company controls cash burn. The most important near term catalyst now looks like execution on Furoscix ReadyFlow’s US launch, with IPF program progress a close second. The biggest current risk remains MannKind’s reliance on a still concentrated product base, and these new data points do not yet change that concentration risk in a material way.

    The Furoscix ReadyFlow approval is particularly relevant here, because it adds an at home, IV equivalent diuretic option aimed at reducing heart failure and CKD related hospital use. For MannKind, it provides another avenue to test whether it can convert device based innovation into sustained physician adoption and payer support, alongside its efforts in inhaled nintedanib and the newly approved pediatric Afrezza indication.

    Yet, against these positives, the concentration risk around Afrezza, Tyvaso DPI royalties and a still emerging pipeline is something investors should be aware of, especially if...

    Read the full narrative on MannKind (it's free!)

    MannKind's narrative projects $554.4 million revenue and $85.4 million earnings by 2029.

    Uncover how MannKind's forecasts yield a $7.59 fair value, a 94% upside to its current price.

    Exploring Other Perspectives

    MNKD 1-Year Stock Price Chart
    MNKD 1-Year Stock Price Chart

    Before this news, the most pessimistic analysts expected only about 7.4 percent annual revenue growth to roughly US$447,000,000 and earnings of about US$4,700,000 by 2029, reflecting deeper concern about MannKind’s dependence on a few products and high spending; their view highlights how far opinions can differ and why it is worth comparing that stance with your own take on nintedanib DPI and Furoscix ReadyFlow.

    Explore 3 other fair value estimates on MannKind - why the stock might be worth over 2x more than the current price!

    Reach Your Own Conclusion

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    No Opportunity In MannKind?

    Every day counts. These free picks are already gaining attention. See them before the crowd does:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.